Paris, France — 15 January 2021 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase…
Paris, France — 18 December 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a phase…
Cash and cash equivalents of €22.1 million1 as of 30 September 2020 Paris, France —…
Paris, France — 15 October 2020 at 08:00am — Lysogene (FR0013233475 – LYS), a Phase…
Cash and cash equivalent of €23.8 million1 as of 30 June 2020 FDA letter on…
Novel AAV gene therapy approach for neuronopathic Gaucher disease and Parkinson disease with GBA1 mutations…
Shareholders approved all proposed resolutions Paris, France — 26 June 2020 — Lysogene (FR0013233475-LYS) held…
Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Paris, France — 05 June 2020 at 08:00am CEST— Lysogene (FR0013233475 – LYS), a Phase…
Lyon and Paris, France, May 26, 2020 – Novasep, a leading supplier of services and…
Paris, France — 20 May 2020 at 06:00pm CEST— Lysogene (FR0013233475 – LYS), a Phase…